TY - JOUR
T1 - Albumin nanostructures as advanced drug delivery systems
AU - Karimi, Mahdi
AU - Bahrami, Sajad
AU - Ravari, Soodeh Baghaee
AU - Zangabad, Parham Sahandi
AU - Mirshekari, Hamed
AU - Bozorgomid, Mahnaz
AU - Shahreza, Somayeh
AU - Sori, Masume
AU - Hamblin, Michael R.
N1 - Publisher Copyright:
© 2016 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2016/11/1
Y1 - 2016/11/1
N2 - Introduction: One of the biggest impacts that the nanotechnology has made on medicine and biology, has been in the area of drug delivery systems (DDSs). Many drugs suffer from serious problems concerning insolubility, instability in biological environments, poor uptake into cells and tissues, sub-optimal selectivity for targets and unwanted side effects. Nanocarriers can be designed as DDSs to overcome many of these drawbacks. One of the most versatile building blocks to prepare these nanocarriers is the ubiquitous, readily available and inexpensive protein, serum albumin. Areas covered: This review covers the use of different types of albumin (human, bovine, rat, and chicken egg) to prepare nanoparticle and microparticle-based structures to bind drugs. Various methods have been used to modify the albumin structure. A range of targeting ligands can be attached to the albumin that can be recognized by specific cell receptors that are expressed on target cells or tissues. Expert opinion: The particular advantages of albumin used in DDSs include ready availability, ease of chemical modification, good biocompatibility, and low immunogenicity. The regulatory approvals that have been received for several albumin-based therapeutic agents suggest that this approach will continue to be successfully explored.
AB - Introduction: One of the biggest impacts that the nanotechnology has made on medicine and biology, has been in the area of drug delivery systems (DDSs). Many drugs suffer from serious problems concerning insolubility, instability in biological environments, poor uptake into cells and tissues, sub-optimal selectivity for targets and unwanted side effects. Nanocarriers can be designed as DDSs to overcome many of these drawbacks. One of the most versatile building blocks to prepare these nanocarriers is the ubiquitous, readily available and inexpensive protein, serum albumin. Areas covered: This review covers the use of different types of albumin (human, bovine, rat, and chicken egg) to prepare nanoparticle and microparticle-based structures to bind drugs. Various methods have been used to modify the albumin structure. A range of targeting ligands can be attached to the albumin that can be recognized by specific cell receptors that are expressed on target cells or tissues. Expert opinion: The particular advantages of albumin used in DDSs include ready availability, ease of chemical modification, good biocompatibility, and low immunogenicity. The regulatory approvals that have been received for several albumin-based therapeutic agents suggest that this approach will continue to be successfully explored.
KW - Human serum albumin
KW - bovine serum albumin
KW - drug delivery systems
KW - nanoparticles
KW - ovalbumin
UR - http://www.scopus.com/inward/record.url?scp=84991384253&partnerID=8YFLogxK
U2 - 10.1080/17425247.2016.1193149
DO - 10.1080/17425247.2016.1193149
M3 - Review article
C2 - 27216915
AN - SCOPUS:84991384253
SN - 1742-5247
VL - 13
SP - 1609
EP - 1623
JO - Expert Opinion on Drug Delivery
JF - Expert Opinion on Drug Delivery
IS - 11
ER -